Neomorph

Neomorph is a privately held biotechnology company headquartered in San Diego, California, founded in 2020. The company is focused on the discovery and development of molecular glue degraders, a class of small-molecule medicines that repurpose the cell's own protein-degradation machinery to eliminate disease-causing proteins. The name "Neomorph" is drawn from an old genetic concept describing a structure or function not derived from an ancestor that confers novel activity — an idea the company says sits at the core of its science. Neomorph's scientific premise is that roughly 85% of the human proteome remains out of reach of traditional small-molecule drugs and is considered "undruggable." Molecular glue degraders, by contrast, bypass the need for conventional ligand-binding pockets. They bind an E3 ubiquitin ligase, reshape it to create a new or "neomorphic" binding surface, and recruit target proteins for ubiquitination and degradation. Approved drugs such as pomalidomide and indisulam are cited by the company as validation of the molecular glue mechanism. The company describes its platform as the world's largest proprietary molecular glue target space, featuring multiple novel degrons, unique glue libraries, and an expansive portfolio of E3 ubiquitin ligases. Neomorph says its next-generation discovery platform allows for the identification of thousands of high-confidence protein targets and multiple novel degrons, and the enablement of many E3 ligase systems — moving molecular glue discovery away from serendipity toward a systematic process. Neomorph states that it is building a clinical-stage pipeline spanning oncology, immunology, neurodegeneration, virology, and cardiometabolic disease, among other areas, and that it works alongside multiple pharmaceutical partnerships. The company positions itself as a pioneer of molecular glue degrader technology and as a team that laid much of the field's groundwork. It is headquartered in San Diego, California.

Neomorph was founded in 2020 and is headquartered in San Diego, California. The company takes its name from an old genetic concept: a structure or function not derived from an ancestor that confers novel activity. According to the company, that idea sits at the core of its science, and its molecular glue degraders are intended to open new biological possibilities in treating disease. The company's founding premise addresses a long-standing limitation in drug discovery. Humans possess roughly 20,000 proteins, but only a small fraction has been successfully targeted with therapeutics, leaving many disease-causing proteins "undruggable." Neomorph's approach leverages the cell's built-in degradation machinery: small-molecule molecular glue degraders modify protein function by creating a neomorphic surface that traps and ultimately eliminates problematic proteins in their entirety. Historically, identifying new molecular glues was slow, blind, and dependent on serendipitous discovery. Neomorph states that its next-generation discovery platform illuminates that process, making molecular glue identification no longer a matter of random chance. The platform allows for the discovery of thousands of high-confidence protein targets and multiple novel degrons, and the enablement of many E3 ligase systems. Neomorph describes its platform as the world's largest proprietary molecular glue target space, featuring multiple novel degrons, unique glue libraries, and an expansive portfolio of E3 ubiquitin ligases. The company says it has access to hundreds of E3 ligases and multiple proprietary degrons, and that its platform differs from the typical drug discovery workflow. Neomorph reports that it is building a clinical-stage pipeline across oncology, immunology, neurodegeneration, virology, cardiometabolic disease, and more, alongside multiple pharmaceutical partnerships. The company positions itself as positioned to elucidate the gluable proteome at large.

• 2020

  Neomorph founded and headquartered in San Diego, California.

Pioneer of molecular glue degrader technology aiming to make the previously undruggable proteome targetable.

• Molecular glue degraders

  Small-molecule medicines that bind an E3 ubiquitin ligase, create a neomorphic surface, and recruit disease-causing proteins for degradation.

• Next-generation molecular glue discovery platform

  Platform featuring the world's largest proprietary molecular glue target space, multiple novel degrons, unique glue libraries, and an expansive portfolio of E3 ubiquitin ligases.

1. 1Neomorph | Molecular Glue Degradersneomorph.com
2. 2About Neomorph | Our Story and Teamneomorph.com
3. 3Neomorph | Our Platform How We Design Molecular Gluesneomorph.com
4. 4Neomorphwikidata.org